Total Payments
$21,095
2024 Payments
$2,813
Companies
88
Transactions
972
Medicare Patients
31,032
Medicare Billing
$10.3M
Payment Breakdown by Category
Food & Beverage$16,417 (77.8%)
Consulting$3,000 (14.2%)
Education$1,453 (6.9%)
Travel$224.24 (1.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,417 | 939 | 77.8% |
| Consulting Fee | $3,000 | 1 | 14.2% |
| Education | $1,453 | 31 | 6.9% |
| Travel and Lodging | $224.24 | 1 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Heron Therapeutics, Inc. | $3,410 | 4 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $1,742 | 96 | $0 (2024) |
| PFIZER INC. | $929.89 | 67 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $863.10 | 45 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $776.51 | 60 | $0 (2024) |
| Janssen Biotech, Inc. | $770.03 | 42 | $0 (2024) |
| Amgen Inc. | $735.70 | 39 | $0 (2024) |
| Merck Sharp & Dohme LLC | $653.73 | 37 | $0 (2024) |
| Celgene Corporation | $638.40 | 37 | $0 (2024) |
| Genentech USA, Inc. | $627.25 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,813 | 130 | Gilead Sciences, Inc. ($308.46) |
| 2023 | $2,247 | 110 | Novartis Pharmaceuticals Corporation ($228.29) |
| 2022 | $2,576 | 146 | Novartis Pharmaceuticals Corporation ($168.72) |
| 2021 | $3,143 | 164 | Novartis Pharmaceuticals Corporation ($290.47) |
| 2020 | $1,546 | 89 | AstraZeneca Pharmaceuticals LP ($193.53) |
| 2019 | $1,641 | 97 | Genentech USA, Inc. ($164.72) |
| 2018 | $2,239 | 129 | Novartis Pharmaceuticals Corporation ($266.61) |
| 2017 | $4,889 | 107 | Heron Therapeutics, Inc. ($3,390) |
All Payment Transactions
972 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $18.83 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 12/20/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $31.88 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Oncology | ||||||
| 12/17/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.68 | General |
| 12/11/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: HEMATOLOGY | ||||||
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $27.84 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.74 | General |
| Category: Oncology | ||||||
| 11/26/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.93 | General |
| 11/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: DESMOID TUMORS | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 74 | 7,420 | 243,847 | $7.6M | $2.3M |
| 2022 | 73 | 7,723 | 272,778 | $7.9M | $2.5M |
| 2021 | 78 | 7,727 | 270,369 | $7.5M | $2.4M |
| 2020 | 75 | 8,162 | 347,546 | $9.4M | $3.1M |
Total Patients
31,032
Total Services
1,134,540
Medicare Billing
$10.3M
Procedure Codes
300
All Medicare Procedures & Services
300 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 28,200 | $2.8M | $1.2M | 41.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 92 | 16,501 | $660,040 | $301,336 | 45.7% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 15 | 4,680 | $547,560 | $110,814 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 615 | 1,131 | $142,506 | $101,270 | 71.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 65 | 98,250 | $393,000 | $85,244 | 21.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 114 | 848 | $237,440 | $80,325 | 33.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 180 | 597 | $155,220 | $78,999 | 50.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 14 | 744 | $465,000 | $68,306 | 14.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 687 | 2,552 | $244,992 | $26,396 | 10.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 777 | 3,033 | $151,650 | $23,049 | 15.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 338 | 397 | $35,730 | $22,483 | 62.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 132 | 132 | $52,800 | $21,329 | 40.4% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 141 | $91,650 | $18,632 | 20.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 79 | 683 | $54,640 | $14,672 | 26.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 94 | 1,235 | $86,450 | $13,998 | 16.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 112 | 268 | $42,880 | $12,126 | 28.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 46 | 256 | $40,960 | $12,099 | 29.5% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 511 | 1,968 | $55,104 | $11,645 | 21.1% |
| 83735 | Magnesium level | Office | 2023 | 458 | 1,482 | $71,136 | $9,730 | 13.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 95 | $14,250 | $8,755 | 61.4% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 200 | 430 | $47,300 | $8,753 | 18.5% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 102 | 754 | $90,480 | $7,096 | 7.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 153 | 668 | $43,420 | $6,783 | 15.6% |
| 96416 | Administration of prolonged chemotherapy into vein | Office | 2023 | 12 | 71 | $21,300 | $6,547 | 30.7% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 119 | 351 | $38,610 | $6,506 | 16.8% |
About Dr. John Doster, M.D
Dr. John Doster, M.D is a Hematology & Oncology healthcare provider based in Anderson, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982670147.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Doster, M.D has received a total of $21,095 in payments from pharmaceutical and medical device companies, with $2,813 received in 2024. These payments were reported across 972 transactions from 88 companies. The most common payment nature is "Food and Beverage" ($16,417).
As a Medicare-enrolled provider, Doster has provided services to 31,032 Medicare beneficiaries, totaling 1,134,540 services with total Medicare billing of $10.3M. Data is available for 4 years (2020–2023), covering 300 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Anderson, SC
- Active Since 02/27/2006
- Last Updated 04/09/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982670147
Products in Payments
- SUSTOL (Drug) $3,390
- KEYTRUDA (Biological) $517.42
- OPDIVO (Biological) $454.55
- Lenvima (Drug) $395.44
- Nubeqa (Drug) $376.92
- IBRANCE (Drug) $365.30
- TAGRISSO (Drug) $331.92
- TECENTRIQ (Biological) $327.35
- CALQUENCE (Drug) $316.09
- KISQALI (Drug) $314.77
- PROMACTA (Drug) $313.07
- IMBRUVICA (Drug) $256.14
- TUKYSA (Drug) $227.15
- Enhertu (Drug) $216.49
- LIBTAYO (Biological) $215.38
- Cabometyx (Drug) $206.63
- VERZENIO (Drug) $204.56
- ERLEADA (Drug) $199.89
- Revlimid (Drug) $188.47
- PADCEV (Biological) $185.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Anderson
Jeffrey Delo, Md, MD
Hematology & Oncology — Payments: $13,853
Hematology & Oncology $13,853
Tahir Naqvi, Md, MD
Hematology & Oncology — Payments: $9,347
Hematology & Oncology $9,347
Brian Eddy, Md, MD
Hematology & Oncology — Payments: $6,163
Hematology & Oncology $6,163
Dr. Jay Nayak, M.d, M.D
Hematology & Oncology — Payments: $4,545
Hematology & Oncology $4,545
Hazim Rimawi, Md, MD
Hematology & Oncology — Payments: $3,152
Hematology & Oncology $3,152
Rajeev Malik, M.d, M.D
Hematology & Oncology — Payments: $666.86
Hematology & Oncology $666.86